BLOG

HCP

FDA Clears Phase 2B Study Testing LSD for Anxiety

The US Food and Drug Administration has cleared an Investigational New Drug application allowing MindMed to move forward with a phase 2b dose-optimization trial of MM-120 for the treatment of generalized anxiety disorder (GAD).